17 stories found
The biotechnology company will present preclinical findings for multiple development candidates targeting Duchenne Muscular Dystrophy at the 27th Annual NMSG Scientific Meeting.
Dyne Therapeutics' stock slipped after the company priced an upsized $375 million public offering at $20.50 per share, following an earlier announcement of a $300 million stock offering that led to a 14% drop in shares.
An analysis compares Dyne Therapeutics and Vertex Pharmaceuticals to determine which drug innovator stock presents a better investment opportunity for 2026.
Dyne Therapeutics (DYN) has announced the successful conclusion of patient enrollment for its Phase 1/2 ACHIEVE clinical trial, marking a significant milestone in its drug development.
Dyne Therapeutics stock has seen a significant 40% increase, even as a biotech fund recently disclosed selling $14 million worth of its shares. This divergence in activity presents an interesting market dynamic for the company.
Dyne Therapeutics (DYN) saw its stock rise by 11.8% following a significant triple-digit price target upgrade from analysts.
Wainwright has reiterated its stock rating for Dyne Therapeutics, citing the company's trial outlook as a key factor in its assessment.
Dyne Therapeutics is generating optimism with its Force Platform, highlighting its potential in therapeutic development.
An analysis comparing Dyne Therapeutics and Viking Therapeutics to determine which healthcare stock might be a better investment by 2026.
Dyne Therapeutics (DYN) has reached a significant regulatory milestone, indicating progress in its development pipeline.
Multiple biotech and pharmaceutical companies, including Legend Biotech, Corcept Therapeutics, and Ultragenyx, have released updates on their drug pipelines, clinical trial data, and regulatory interactions, impacting market outlook.
Shares of Dyne Therapeutics experienced a slide following the pricing of its $375 million public offering.
A comparison evaluates Dyne Therapeutics and Recursion Pharmaceuticals to determine which development-stage pharma stock presents a better buying opportunity in 2026.
Dyne Therapeutics has expanded its debt facility with Hercules Capital, increasing the total to $400 million.
Dyne Therapeutics' stock saw a significant increase following the commencement of a late-stage clinical trial for its Duchenne muscular dystrophy therapy.
Dyne Therapeutics (DYN) has shared important details concerning its pivotal drug candidates, drawing attention from the pharmaceutical sector.